-
Rail journey offers a slower route to a Berlin city break
-
Energy bill plan could use HMRC income data to target support
-
Arsenal control title race as Manchester United fall into bottom three
-
Business owner earning £6,000 a month tackles £70,000 debt
-
Suspected Krakow gunman dies after attack that killed six
-
Nvidia chief faces inquiry after disclosing affair with suspected Chinese agent
-
Carrick backs Dalot after hostile reception from Manchester United fans
-
Comet returns as online electrical marketplace 14 years after collapse
-
Aston Villa Defy History With Rare Victory at Old Trafford
-
Brussels Education Unions Schedule Major November Protest Over Funding and Reforms
-
Crowds Gather at San Francisco Park for Elizabeth Holmes Lookalike Tournament
-
Hancock Health Expands Robot Specimen Delivery to Parkway Building, Adding Scheduled and On-Demand Runs to the Lab
-
Releaf Unveils UK-first THCV for Weight Management
-
Gabriel Provides Corporate Update
-
AsiaFIN's Insite MY Holdings and MENA Insite MY Sign Distributorship Agreement and Announce Second Bank Customer in Saudi Arabia
-
Ai4 Celebrates Successful Debut of Applied AI Research Conference (AAIRC), Bridging Academic Research and Industry Innovation
-
Medicus Pharma to Highlight Rationale for CD228V Co-Development and License Agreement
-
Nextech3D.ai Closes $720,000 Management-Led Private Placement
-
CoTec Holdings Corp. Notes HyProMag USA Advances North Texas Rare Earth Magnet Facility With First Major Equipment Delivery
-
Silver Storm Reports Concentrate Deliveries from La Parrilla
-
Ispire Technology Inc. Reports First Quarter Fiscal Year 2027 Financial Results
-
HyProMag USA Advances North Texas Rare Earth Magnet Facility With First Major Equipment Delivery
-
Hillcrest and Equipmake Sign Definitive Agreement to Jointly Develop and License ZVS Inverter Technology for Heavy-Duty Electric Vehicles
-
Tintina Mines Intersects 460m at 0.50% CuEq at the Dos Amigos Copper-Gold Project in Chile
-
Pace Launches Three-Business-Day Culture-Based 'L. pneumophila' Testing
-
Opti Digital Launches NEXA, an AI-Powered Intelligence Layer
-
DataMEDS AI Announces Corexa Pharmacy's First Commercial Sale of Compounded Peptides Under FDA Enforcement Discretion Policy
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 09
-
Making Your Home Safer for Aging Parents: Accessibility Renovations That Add Value
-
New 401k Gold IRA Investment Guide Explains the Best Way to Invest in Gold for Retirement (2026 Update)
-
United States Antimony Corporation Announces Webcast Time set for Thursday, November 12, 2026 at 4:15 PM ET to Report on Third Quarter and Nine Months Ended September 30, 2026 Financial and Operating Results
-
Pacific Edge Labs Publishes More Than 120 Independent Lab Reports, Each Listed With the Testing Lab's Own ID
-
Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC(R) in Israel
-
Modular Medical Completes Comprehensive Patient Market Research Study with Thrivable, Reinforcing Strong Interest in Simplified Insulin Delivery
-
Shelfietech Launched New Retail Software Platform
-
A Holiday-Season Moment for Penny-Stock Followers and Microcap Visionaries as Elektros Moves Its EV Patent Forward
-
Dolphin Subsidiary 42West Drives Global Communications Behind Box Office Leaders Godzilla Minus Zero and Ramayana
-
Visterra Landscape Group Expands Into Arkansas With Strategic Investment In Little Rock Landscape
-
Santa Claus Has Come Early: Elektros Brings An Early-Christmas Spark To Its Patented EV Charging Vision
-
SMX Is Building a Verifiable Identity Layer for Fashion, From Cotton Fields to Luxury Resale
-
Gladstone Land Corporation Earnings Call and Webcast Information
-
The Metals Royalty Company to Host Corporate Update Webinar on November 16, 2026
-
Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors
-
Eylsia Nicolas Launches Global "Wake Me Up" Franchise After Surpassing 100 Million Meta Views in One Week
-
BioLargo Targets Growing Industrial PFAS Market with MasterClass at International Water Conference
-
Jericho Energy Ventures to Participate in Cantor Convergence 4th Annual Crypto and AI Infrastructure Conference
-
IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update
-
Tectonic Metals Adds Mine Development and Alaska Native Partnership Leaders Ahead of 2027 Mineral Resource Estimate and Preliminary Economic Assessment
-
iPS Cell Research Accelerates Drug Discovery for ALS and Spinal Cord Injury
-
Central Tokyo Apartment Rents Forecast to Rise 11% by 2030
CBD Life Sciences Inc. (OTC: CBDL) Launches Tremendous Energy & Weight-Loss Diet Hemp-Free Gummies
Global functional gummy supplements market projected to surpass $50 billion by 2030 - CBDL expands into two of the fastest-growing segments in wellness and performance nutrition.
SCOTTSDALE, ARIZONA / ACCESS Newswire / October 28, 2025 / CBD Life Sciences Inc. (OTC:CBDL), an emerging leader in wellness innovation and nutraceutical advancement, proudly announces the official launch of its new Energy Boost and Diet & Weight-Loss Hemp-Free Gummies, both formulated with 100 mg vegan, plant-based ingredients. These new releases position CBDL at the intersection of two of the most explosive consumer categories in the global supplement market: energy enhancement and weight management.
An Expanding Billion-Dollar Market Opportunity
According to Fortune Business Insights and Grand View Research, the global gummy supplements market is projected to skyrocket from $23.93 billion in 2023 to over $52 billion by 2030, registering a CAGR of 11.8-13%. Within that, functional wellness gummies - focused on energy, fitness, and weight control - represent one of the fastest-growing categories in nutraceuticals.
With these launches, CBDL now competes directly in a high-margin, mainstream market appealing to millions of consumers who prefer convenient, hemp-free, and vegan-friendly supplements.
Product Overview
Energy Boost Gummies - 100 mg
Crafted for active lifestyles and peak performance, these vegan gummies feature a green-tea extract + caffeine + BCAA + L-Arginine blend, offering a clean energy lift with a refreshing energy-drink flavor profile. Designed for athletes, professionals, and everyday consumers needing focus, stamina, and clarity.
Diet & Weight-Loss Gummies - 100 mg
This proprietary hemp-free formula combines Maca Root Powder, Caffeine, Yohimbe Extract, Guarana, and Bitter Orange Extract to help support metabolism, fat burning, and appetite control naturally. Entirely vegan, non-GMO, and formulated with plant-based ingredients for health-conscious consumers seeking results without compromise.
Positioned for Scale - A Strategic Expansion Beyond CBD
By entering the functional wellness market, CBDL is:
Diversifying revenue beyond hemp and CBD-exclusive verticals, appealing to mainstream retailers and broader audiences.
Expanding shelf potential in fitness, nutrition, and pharmacy channels, both online and in brick-and-mortar distribution.
Capitalizing on sustained consumer demand for clean-label, vegan, and hemp-free products across multiple demographics.
Leveraging its existing e-commerce and retail partnerships to roll out these SKUs at scale, with strong early interest from wellness distributors and private-label opportunities.
Management Commentary
"This is a defining moment for our company," said Lisa Nelson, President & CEO of CBD Life Sciences Inc.
"We've built our brand on trust and results. With these hemp-free, high-performance gummies, we're no longer just a CBD company - we're a full-scale wellness brand entering billion-dollar markets that reward innovation and quality. Investors should understand how significant this is - these launches can open new sales channels, increase margins, and attract large-scale distribution opportunities nationwide."
The Bigger Picture
CBDL's new gummies represent more than a product drop - they signal the company's transformation into a next-generation wellness platform. As consumer trends shift toward performance nutrition, daily energy, and weight-management support, CBDL's research-backed formulations position it for sustained growth, profitability, and heightened investor visibility within the OTC small-cap market.

About CBD Life Sciences Inc. (OTC: CBDL)
CBD Life Sciences Inc. is a publicly traded health-and-wellness company focused on developing innovative cannabinoid and plant-based nutraceuticals. Through its flagship brand, The CBD Vault, the company offers premium wellness products including topicals, tinctures, edibles, beverages, and functional supplements. CBDL continues to expand its product portfolio and retail footprint while maintaining commitment to scientific innovation, consumer safety, and shareholder value creation.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
Website: https://www.thecbdvault.com
IR Contact: [email protected]
Stay Connected & Be the First to Try Our New Functional Mushroom Products!
Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz
Mushroom Madness Website: https://www.mushroommadness.shop
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
[email protected]
4802091720
SOURCE: CBD Life Sciences, Inc.
View the original press release on ACCESS Newswire
L.Mason--AMWN